DUBLIN, Ireland, May 03, 2022 – Deciphex have announced today that it is now a full service provider in Pathology AI and Quantitative Pathology. This service will include the provision of their software solution, Patholytix Preclinical, as well as outsourced GPU infrastructure to power artificial intelligence (AI) activities, and AI and Data Science expertise from Deciphex’s in-house team of experts. This service will be provided and deployed at a fraction of the cost and time of internal AI programs. 

Deciphex is positioning itself to become one of the biggest players in pathology artificial intelligence through the provision of this service that will allow CRO, pharmaceutical, and biotechnology companies of any size to adopt AI easily in their non-clinical digital pathology workflows.

“There is mounting evidence that the application of AI methodologies to pathology workflows can help with the development of decision support tools” says  Dr.Trevor McKee, Director of Commercial AI Services in Research Pathology at Deciphex. “However, adoption of AI in non-clinical study review can be complicated, especially for pathologists used to reviewing slides in more traditional microscopy workflows. Additionally, pathology departments in pharmaceutical or biotech companies often do not have the time, expertise, or infrastructure to implement AI effectively.”

Offering a complete managed solution to fully enable customers with advanced AI capabilities to enable more efficient study review, Deciphex's new service aims to overcome these challenges. The service is explained by Dr. Trevor McKee:

“We have a large team of Data Scientists that have extensive experience in image processing and AI model development who can work with customers to design & run experiments on their behalf specific to their research needs. Our infrastructure is scalable, secure, and trusted by many of the largest multinational CROs and pharmaceutical companies for handling high volume safety and toxicity studies. All of your AI models can be readily accessed through our industry-leading platform, Patholytix Preclinical, and these services are securely accessible from anywhere within your organisation.”

Deciphex’s service is enabled through their software, Patholytix AI. This platform consolidates state-of-the-art AI models into a fully integrated study review workflow, facilitating on-demand access to quantitative pathology outputs providing powerful decision support that help improve the efficiency of study reporting.

Speaking about the potential uses of the service, Dr. Mc Kee says:

“Our powerful AI models make many of the everyday tasks of a pathology department less laborious and time-consuming. With our AI capabilities, users can automate tasks they regularly perform; whether that is to simplify the arduous task of image quality control during scanning; or to provide decision support on skilled tasks such as cell density variation and lesion detection. Not only can our solutions simplify the slide review process, AI implementation can also provide workflow enhancements, with quantitative pathology measurements that can provide additional insight to help improve study review”.

He emphasises that this can be deployed in a more cost effective manner than setting up an AI department in-house.

“Our goal at Deciphex is to be your complete outsourced partner for Artificial Intelligence applications in Research Pathology” says Vice President of Sales & Marketing of Research Pathology, Colin Doolan. “We can provide you with everything you need to adopt AI immediately - software, infrastructure, and expertise”.

Find out more at www.patholytix.com/patholytix-ai or email aiservices@deciphex.com.

‍About Deciphex‍

Deciphex is an Irish-based software company focused on developing digital pathology-based solutions for clinical and research pathology. Our ambition is to deliver solutions that provide tangible productivity benefits to pathologists, eliminating low-level tasks so they can focus on the critical content. We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future, offering a solution to the pending challenges in supply/demand in pathology services. Deciphex is at the forefront of this revolution with cleverly positioned solutions that deliver on the biggest problems facing pathology today. 

INVESTOR CONTACT

Mairin Rafferty
Chief Operating Officer
+353 86 1737932
mairin.rafferty@deciphex.com

MEDIA CONTACT

Charli-Ann Lynch
Preclinical Marketing Associate
+353 872402459
charli-ann.lynch@deciphex.com

‍